High-dose RSV mRNA vaccine
Vaccine
Sinovac Biotech Co., LtdHigh-dose RSV mRNA vaccine is one of 27 biologic programs targeting Herpes Zoster. It is currently in development.
1
Indications
2
Total Trials
2
Active Trials
26
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
92 competitors in Herpes Zoster
#DrugCompanyPhaseTrials
1Fluzone
SanofiPhase 3
Herpes Zoster Vaccine 1437173a
GSKPhase 3
GSK 257049
GSKPhase 3
Rsvpref3 Vaccine
GSKPhase 3
Boostrix
GSKPhase 3
Prevenar13
GSKPhase 3
Valtrex
GGlaxo Dba Glaxosmithkline
Phase 2
Hz/su VACCINE
GSKPhase 3
Valaciclovir
GSKPhase 2
Influenza Vaccine
NovartisPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for High-dose RSV mRNA vaccine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Vaccine[2]
- Company